Natural Product Discovery for Antibacterial Drug Development

Natural products—complex small molecules produced by microbes, plants and marine organisms—have underpinned antibacterial therapy since the mid-20th century. After a golden era of antibiotic discovery, high rediscovery rates and silent biosynthetic pathways led to a dry pipeline. Advances in genome sequencing, bioinformatics and analytical chemistry have reignited interest in natural sources. Genome mining reveals cryptic biosynthetic gene clusters encoding novel scaffolds; synthetic-biology tools enable the refactoring and heterologous expression of these clusters; and integrated omics (metabolomics, transcriptomics and proteomics) connects genetic potential to chemical output. Exploration of under-explored microbiomes—soil, marine environments and animal-associated communities—has uncovered unique secondary metabolites with activity against multidrug-resistant bacteria. Complementary culture-based innovations, such as co-cultivation and elicitor screening, further expand chemical diversity. Together, these multidisciplinary strategies are delivering new chemical classes, informing rational lead optimisation and driving preclinical candidates that address global antimicrobial resistance.

Research from Nature Portfolio

Recent studies have demonstrated the power of genome mining to uncover hidden biosynthetic potential in diverse bacteria. Sophisticated bioinformatic pipelines now predict hundreds of previously uncharacterised gene clusters from environmental and microbiome-derived genomes. By coupling these predictions with heterologous expression platforms and pathway refactoring, researchers have successfully activated silent clusters to isolate novel antibacterial scaffolds with unprecedented modes of action. Parallel developments in mass-spectrometry-based metabolomics enable rapid dereplication and structural elucidation, accelerating the transition from genomic discovery to chemical characterisation. These integrated approaches have begun to yield compounds that inhibit critical targets in drug-resistant pathogens, illustrating a new paradigm for antibiotic discovery driven by sequence-to-structure workflows.

Natural Product Discovery for Antibacterial Drug Development publication trend

The graph below shows the total number of articles in natural product discovery for antibacterial drug development across all publications each year (not limited to Nature Index journals).

Technical terms

Biosynthetic gene cluster: A contiguous set of genes encoding enzymes and regulatory proteins responsible for the production of a specific natural product.

Genome mining: Computational analysis of genomic data to predict and prioritise biosynthetic gene clusters for novel compound discovery.

Heterologous expression: Introduction and expression of a biosynthetic gene cluster in a non-native host organism to activate compound production.

Metabolomics: The large-scale study of small molecules produced by organisms, often using mass spectrometry to profile and identify metabolites.

Silent pathway: A biosynthetic gene cluster that is not expressed, or expressed at undetectable levels, under standard laboratory conditions.

Cyclic peptide: A peptide whose amino- and carboxy-termini are linked, forming a ring structure that often confers enhanced stability and biological activity.

References

1. Mining and unearthing hidden biosynthetic potential. Nature Communications (2021).
2. Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?. Antibiotics (2018).
3. An Optimized Synthetic-Bioinformatic Natural Product Antibiotic Sterilizes Multidrug-Resistant Acinetobacter baumannii-Infected Wounds. mSphere (2018).
4. Cyclic Peptides for Drug Development. Angewandte Chemie (2023).
5. In Vitro and In Silico Studies of Antimicrobial Saponins: A Review. Processes (2023).
6. Unveiling the Ocean's Arsenal: Successful Integration of Marine Metabolites into Disease Management. UTTAR PRADESH JOURNAL OF ZOOLOGY (2024).
7. mSphere of Influence: Synthetic Biology of Natural Product Biosynthesis. mSphere (2020).
8. Rare Actinomycetes from Undiscovered Sources as a Source of Novel Antimicrobial Agents to Control Multidrug-Resistant Bacteria. International Journal Of Pharmaceutical Research And Allied Sciences (2022).